Abstract:Background: The application of positron emission tomography/computed tomography (PET/CT) helps provide accurate clinical staging for lung cancer patients. However, the effects and trends in early-stage lung cancer remain unclear. The aim of this study was to compare differences between clinical stage I lung cancer patients who received PET/CT for staging and those who did not. Methods: Data were obtained from the Taiwan Society of Cancer Registry. There were 6587 clinical stage I lung cancer patients between 2009 and 2014 analyzed in this study. We compared the characteristics of the PET/CT and no PET/CT groups. After propensity score matching, it resulted in both groups having 2649 patients. We measured the overall survival rates of all clinical stage I lung cancer patients and the overall survival rates of patients with PET/CT and without PET/CT. Results: The 1-, 3-, and 5-year survival rates of all clinical stage I lung cancer patients were 97.2%, 88.2%, and 79.0%, respectively. Patients with a larger tumor size tended to receive PET/CT for staging (stage Ib: 38.25% vs. 27.82%, p < 0.0001) and a larger resection (lobectomy: 74.62% vs. 66.61%, p < 0.0001). The 5-year survival rates were 79.8% in the PET/CT group and 78.2% in the no PET/CT group after propensity score matching (p = 0.6528). Conclusions: For clinical stage I lung cancer in Taiwan, patients with larger tumor sizes tend to have PET/CT for staging. Although PET/CT provided more precise clinical staging, these patients still received larger resections and had more pathological migration. However, there was no overall survival rate benefit after PET/CT.

What problem does this paper attempt to address?

The paper attempts to address the issue of evaluating the prognostic value of Positron Emission Tomography/Computed Tomography (PET/CT) in patients with clinical stage I lung cancer. Specifically, the study aims to compare the survival rate differences between clinical stage I lung cancer patients who underwent PET/CT staging and those who did not. ### Research Background - **Problem Background**: PET/CT is widely used in the clinical staging of lung cancer patients, helping to provide more accurate staging. However, for early-stage lung cancer (especially clinical stage I), the effectiveness and trends of PET/CT remain unclear. - **Research Objective**: To explore the prognostic value of PET/CT in these patients by comparing the characteristics and survival rates of clinical stage I lung cancer patients who underwent PET/CT staging and those who did not. ### Research Methods - **Data Source**: The study data were obtained from the Taiwan Cancer Registry (TSCR), covering the period from 2009 to 2014. - **Study Design**: A retrospective analysis was conducted, using propensity score matching to reduce bias. - **Sample Selection**: A total of 6587 clinical stage I lung cancer patients were included, of which 2727 underwent PET/CT staging and 3860 did not. - **Main Indicator**: The overall survival rates of the two groups of patients were compared. ### Main Results - **Patient Characteristics**: - Patients who underwent PET/CT staging were older, had larger tumor volumes, and were more likely to undergo lobectomy. - In terms of pathological staging, more patients in the PET/CT group were diagnosed with later-stage pathological staging. - **Survival Rates**: - The 1-year, 3-year, and 5-year survival rates for all clinical stage I lung cancer patients were 97.2%, 88.2%, and 79.0%, respectively. - After propensity score matching, the 5-year survival rates for the PET/CT group and the non-PET/CT group were 79.8% and 78.2%, respectively, with no statistically significant difference (p=0.6528). ### Conclusion - **Main Findings**: Although PET/CT provided more accurate clinical staging, patients who underwent PET/CT staging did not show a significant survival advantage. - **Possible Reasons**: Physicians are more likely to arrange PET/CT staging when the tumor volume is larger or malignancy is suspected, which may lead to more pathological stage migration. ### Discussion - **Advantages of PET/CT**: - Improved accuracy of clinical staging, reduced unnecessary treatments and related complications, and lowered medical costs. - Changed the treatment strategy for some patients, avoiding ineffective surgeries. - **Limitations**: - In practical applications, PET/CT is mostly used for patients with larger tumor volumes or later stages, which may affect the evaluation of its prognostic effect. In summary, this study reveals that the prognostic value of PET/CT in clinical stage I lung cancer patients is limited, although it has advantages in improving the accuracy of clinical staging. Future research needs to further explore how to optimize the application of PET/CT to better serve the diagnosis and treatment of early-stage lung cancer patients.

A Propensity-Match Analysis

Consistency and prognostic value of preoperative staging and postoperative pathological staging using 18F-FDG PET/MRI in patients with non-small cell lung cancer

PET/CT in the Staging of the Non-Small-Cell Lung Cancer

Survival effect of pre-RT PET-CT on cervical cancer: Image-guided intensity-modulated radiation therapy era

The Influence of 18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography on the N- and M-staging and Subsequent Clinical Management of Intrahepatic Cholangiocarcinoma

Evaluation of the factors affecting the maximum standardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung cancer on PET-CT

Correlation Study of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Pathological Subtypes of Invasive Lung Adenocarcinoma and Prognosis.

[The Prognostic Impact of Preoperative PET-CT on Postoperative Recurrence for Completely Resected Stage I Non-Small Cell Lung Cancer].

The impact of PET/CT and brain MRI for metastasis detection among patients with clinical T1-category lung cancer: Findings from a large-scale cohort study

Thorax radiotherapy using 18F-positron emission tomography/computed tomography-guided precision radiotherapy is a prognostic factor for survival in patients with extracranial oligometastatic non-small cell lung cancer:A two-center propensity score-matched analysis

Prognostic factors for survival in unresectable stage III EGFR mutation-positive lung adenocarcinoma: impact of pre-CCRT PET-CT

The Advantage of PET and CT Integration in Examination of Lung Tumors

Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MR and PET/CT

The Effect of Standardized Uptake Value of ~(18)F-FDG-PET on Prognosis of Non-small Cell Lung Cancer

Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer

Application of ~(18)F-FDG PET/CT in Pulmonary Disease:A Report of 419 Cases

Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology

The impact of 18F-FDG PET/CT on the clinlcal strategies of patients with known or suspected lung cancer

Relationship between 18F-FDG PET/CT Semi-Quantitative Parameters and International Association for the Study of Lung Cancer, American Thoracic Society/European Respiratory Society Classification in Lung Adenocarcinomas

Diagnostic accuracy and treatment benefit of PET/CT in staging of colorectal cancer compared to conventional imaging

[Application of ¹⁸F-FDG PET/CT in pulmonary disease: a report of 419 cases].